# 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

> **NCT00028821** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 60 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage III Multiple Myeloma
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** 2-methoxyestradiol
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00028821
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2006-04
- **Final completion:** —
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028821, "2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00028821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*